UL
MCID: LMY014
MIFTS: 56

Leiomyoma, Uterine (UL)

Categories: Cancer diseases, Nephrological diseases, Reproductive diseases

Aliases & Classifications for Leiomyoma, Uterine

MalaCards integrated aliases for Leiomyoma, Uterine:

Name: Leiomyoma, Uterine 57 40
Uterine Leiomyoma 12 37 29 55 6
Uterine Fibroids 43 63 73
Leiomyoma, Uterine, Somatic 57 13
Plexiform Leiomyoma 12 73
Uterine Fibroid 12 15
Leiomyoma of Corpus Uteri 12
Uterus Fibroma 12
Ul 57

Characteristics:

OMIM:

57
Inheritance:
somatic mutation

Miscellaneous:
uterine leiomyomata are found in hereditary leiomyomatosis and renal cell cancer syndrome


HPO:

32
leiomyoma, uterine:
Inheritance somatic mutation autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 150699
Disease Ontology 12 DOID:13223
ICD10 33 D25 D25.9
ICD9CM 35 218 218.9
MeSH 44 D007889
NCIt 50 C3434
SNOMED-CT 68 44598004 95315005
MedGen 42 C0042133
KEGG 37 H01640

Summaries for Leiomyoma, Uterine

MedlinePlus : 43 Uterine fibroids are the most common benign tumors in women of childbearing age. Fibroids are made of muscle cells and other tissues that grow in and around the wall of the uterus, or womb. The cause of fibroids is unknown. Risk factors include being African American or being overweight. Many women with fibroids have no symptoms. If you do have symptoms, they may include Heavy or painful periods or bleeding between periods Feeling "full" in the lower abdomen Urinating often Pain during sex Lower back pain Reproductive problems, such as infertility, multiple miscarriages or early labor Your health care provider may find fibroids during a gynecological exam or by using imaging tests. Treatment includes drugs that can slow or stop their growth, or surgery. If you have no symptoms, you may not even need treatment. Many women with fibroids can get pregnant naturally. For those who cannot, infertility treatments may help. NIH: National Institute of Child Health and Human Development

MalaCards based summary : Leiomyoma, Uterine, also known as uterine leiomyoma, is related to endometriosis and diffuse large b-cell lymphoma, and has symptoms including pelvic pain An important gene associated with Leiomyoma, Uterine is FH (Fumarate Hydratase), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Abraxane and Abstral have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and testes, and related phenotype is uterine leiomyoma.

Disease Ontology : 12 A uterine benign neoplasm derived from the smooth muscle layer of the uterus.

PubMed Health : 63 About uterine fibroids: Many women have benign (non-cancerous) growths known as fibroids in or on their womb (uterus). Most fibroids are small and don't cause any problems. They are usually discovered by chance. Depending on where fibroids are located, they may cause period pain, heavy menstrual bleeding or other symptoms.There are different ways to treat fibroids. The most suitable treatment will greatly depend on a woman’s individual circumstances – such as whether she would still like to have children.Fibroids are made up of muscle cells and connective tissue. Their size, shape and location vary. Fibroids are mainly categorized based on where they are:

Wikipedia : 76 Uterine fibroids, also known as uterine leiomyomas or fibroids, are benign smooth muscle tumors of the... more...

Description from OMIM: 150699

Related Diseases for Leiomyoma, Uterine

Diseases related to Leiomyoma, Uterine via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
# Related Disease Score Top Affiliating Genes
1 endometriosis 30.6 MIR29C MIR196B MIR150
2 diffuse large b-cell lymphoma 30.0 MIR150 MIR139 MIR10A
3 kidney cancer 30.0 MIR29C MIR27A MIR150 FH
4 submucous uterine fibroid 12.6
5 subserous uterine fibroid 12.6
6 blood group--ul system 12.3
7 uterine corpus bizarre leiomyoma 11.3
8 myofibroma 11.3
9 uterus interstitial leiomyoma 11.2
10 uterine corpus lipoleiomyoma 11.2
11 intravenous leiomyomatosis 11.2
12 uterine corpus myxoid leiomyosarcoma 11.2
13 renal cell carcinoma, papillary, 1 11.2
14 uterine corpus epithelioid leiomyoma 11.2
15 uterine corpus dissecting leiomyoma 11.2
16 uterine corpus myxoid leiomyoma 11.2
17 uterine corpus apoplectic leiomyoma 11.2
18 uterine corpus cellular leiomyoma 11.2
19 leiomyoma 10.6
20 herpes simplex 10.6
21 adenomyosis 10.6
22 pseudo-meigs syndrome 10.3
23 sarcoma 10.2
24 uterine benign neoplasm 10.2 HMGA2 FH
25 reproductive organ benign neoplasm 10.2 HMGA2 FH
26 benign metastasizing leiomyoma 10.2
27 umbilical hernia 10.2
28 myoma 10.2
29 leiomyomatosis 10.2
30 infertility 10.2
31 uterine sarcoma 10.2
32 renal cell carcinoma, nonpapillary 10.2
33 endometrial cancer 10.2
34 leiomyosarcoma 10.2
35 pituitary adenoma 10.2 MIR212 MIR197
36 pancreatic ductal adenocarcinoma 10.1 MIR29C MIR203A MIR150
37 laryngotracheitis 10.1
38 oral squamous cell carcinoma 10.1 MIR27A MIR203A MIR197 MIR139 MIR10A
39 lymphangioleiomyomatosis 10.1
40 gastrointestinal stromal tumor 10.1
41 kidney disease 10.1
42 hypoxia 10.1
43 hyperprolactinemia 10.1
44 deficiency anemia 10.1
45 sexual disorder 10.1
46 thrombosis 10.1
47 iron deficiency anemia 10.1
48 iron metabolism disease 10.1
49 vaginal discharge 10.1
50 ovarian cyst 10.1

Graphical network of the top 20 diseases related to Leiomyoma, Uterine:



Diseases related to Leiomyoma, Uterine

Symptoms & Phenotypes for Leiomyoma, Uterine

Symptoms via clinical synopsis from OMIM:

57
Genitourinary Internal Genitalia Female:
uterine leiomyomas, benign


Clinical features from OMIM:

150699

Human phenotypes related to Leiomyoma, Uterine:

32
# Description HPO Frequency HPO Source Accession
1 uterine leiomyoma 32 HP:0000131

UMLS symptoms related to Leiomyoma, Uterine:


pelvic pain

Drugs & Therapeutics for Leiomyoma, Uterine

PubMedHealth treatment related to Leiomyoma, Uterine: 63

Fibroids usually only need to be treated if they are causing fertility problems or could cause problems during pregnancy. The choice of treatment will mainly depend on whether a woman would still like to have children – and how she sees the advantages and disadvantages of the various treatments. The severity of the symptoms and the size and position of the fibroids may also determine which treatments are an option.There is no rush to make a treatment decision. Fibroids usually grow very slowly. So you can take your time to read up on all of the pros and cons of the different treatments. Sometimes it is also a good idea to get several opinions from different doctors.The treatment goals may include the following:Reduce menstrual bleedingRelieve pain, cramps and tensionHelp with difficulties emptying the bladder and digestionPreserve or improve fertilityThe treatment options include:Hormone therapies: The main hormone therapies are hormonal contraceptives to reduce heavy menstrual bleeding, and hormones that prevent the production of estrogens (GnRH analogues).Surgical removal of the fibroid or the entire womb.Closing off the blood vessels that supply the fibroid with blood (uterine fibroid embolization). The aim is to shrink the fibroids.Other procedures like focused ultrasound surgery (FUS). This is a relatively new procedure, and its advantages and disadvantages have not yet been fully studied. FUS uses high-intensity ultrasound waves to heat and destroy the fibroid.Other treatments like painkillers, herbal remedies or acupuncture.NSAID (non-steroidal anti-inflammatory drug) painkillers like ibuprofen or diclofenac have been proven to relieve period pain. But there are no studies that have specifically looked into the effects of NSAIDs in women with fibroids. This is also true for acupuncture. Some herbal remedies have been studied more than others, but there's currently no evidence that they are effective in treating fibroids.

FDA approved drugs:

(show top 50) (show all 240)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Abstral 18 FENTANYL (citrate) ProStrakan January 2011
3
Actiq 18 FENTANYL (citrate) Anesta Corporation November 1998
4
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
5
Afinitor 18 49 EVEROLIMUS Novartis March 2009
6
Akynzeo 18 49 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn October 2014
7
Alimta 18 49 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
8
Aloxi 18 49 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
9
Anzemet 18 DOLASETRON MESYLATE Hoechst Marion Roussel February 1998
10
Aredia 18 49 PAMIDRONATE DISODIUM Chiron August 1996
11
Arimidex 18 49 ANASTROZOLE AstraZeneca January 1996
12
Aromasin Tablets 18 49 EXEMESTANE Pharmacia & Upjohn October 21. 1999
13
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
14
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
15
Avastin 18 49 BEVACIZUMAB Genentech July 2009
16
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
17
Bexxar 18 49 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
18
Blincyto 18 49 BLINATUMOMAB Amgen December 2014
19
Bosulif 18 49 BOSUTINIB MONOHYDRATE Pfizer September 2012
20
Bromfenac 18 BROMFENAC SODIUM Duract, Wyeth-Ayerst Laboratories July 1997
21
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
22
Campath 18 49 ALEMTUZUMAB Berlex Laboratories May 2001
23
Campostar 18 49 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn June 1996
24
CEA-Scan 18 Immunomedics April 1996
25
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
26
Clolar 18 49 CLOFARABINE Genzyme December, 2004
27
Cometriq 18 49 CABOZANTINIB S-MALATE Exelixis November 2012
28
Cyramza 18 49 RAMUCIRUMAB Eli Lilly April 2014
29
Degarelix 18 49 degarelix Ferring Pharmaceuticals December of 2008
30
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
31
Elitek 18 49 RASBURICASE sanofi-aventis October 2009
32
Ellence 18 49 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
33
Eloxatin 18 49 OXALIPLATIN Sanofi-aventis August 2002
34
Emend 18 49 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
35
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
36
Erivedge 18 49 VISMODEGIB Genentech January 2012
37
Erwinaze 18 49 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
38
Ethyol 18 AMIFOSTINE Alza December 8, 1995
39
Eulexin 18 FLUTAMIDE Schering-Plough June 1996
40
Evista 18 49 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
41
Farydak 18 49 PANOBINOSTAT LACTATE Novartis February 2015
42
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
43
Femara 18 49 LETROZOLE Novartis January 2001
44
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
45
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
46
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
47
Gazyva 18 49 OBINUTUZUMAB Genentech October of 2013
48
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
49
Gilotrif 18 49 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
50
Gleevec 18 49 IMATINIB MESYLATE Novartis May 2001

Drugs for Leiomyoma, Uterine (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 282)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53714-56-0 657181 3911
2
Dienogest Approved Phase 4 65928-58-7
3
Goserelin Approved Phase 4,Phase 3,Phase 2 65807-02-5 47725 5311128
4
Desogestrel Approved Phase 4 54024-22-5 40973
5
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
6
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
7
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
8
Dimenhydrinate Approved Phase 4 523-87-5 441281
9
Misoprostol Approved Phase 4,Phase 2,Phase 3 59122-46-2 5282381
10
Calcium Carbonate Approved, Investigational Phase 4,Phase 3 471-34-1
11
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1197-18-8 5526
12
Anastrozole Approved, Investigational Phase 4,Phase 3 120511-73-1 2187
13
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
14
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
15
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
16
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
17
Ferrous fumarate Approved Phase 4 141-01-5
18
Zinc oxide Approved Phase 4 1314-13-2
19
Zinc Approved, Investigational Phase 4 7440-66-6
20
leucovorin Approved Phase 4 58-05-9 6006 143
21
Letrozole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 112809-51-5 3902
22
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
23
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
24
Mifepristone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 84371-65-3 55245
25
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
26
Levonorgestrel Approved, Investigational Phase 4,Phase 2,Not Applicable 17489-40-6, 797-63-7 13109
27
Everolimus Approved Phase 4 159351-69-6 6442177
28
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 6436030 5284616
29
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
30
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 57-83-0 5994
31
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
32
Ibuprofen Approved Phase 4,Not Applicable 15687-27-1 3672
33
Acetaminophen Approved Phase 4 103-90-2 1983
34
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
35
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
36
Morphine Approved, Investigational Phase 4 57-27-2 5288826
37
Prilocaine Approved Phase 4 721-50-6 4906
38
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
39
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
40
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Not Applicable 1177-87-3
41
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
42
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Not Applicable 50-02-2 5743
43
Dinoprostone Approved Phase 4,Not Applicable 363-24-6 5280360
44
Benzocaine Approved, Investigational Phase 4,Not Applicable 94-09-7, 1994-09-7 2337
45
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
46 tannic acid Approved Phase 4,Not Applicable
47
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 56-40-6 750
48
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
49
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
50
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938

Interventional clinical trials:

(show top 50) (show all 366)
# Name Status NCT ID Phase Drugs
1 Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas Unknown status NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
2 Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
3 High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids Unknown status NCT01239641 Phase 4
4 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
5 Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation Unknown status NCT02357563 Phase 4 ulipristal acetate;Leuprolide acetate
6 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Unknown status NCT02601196 Phase 4 Ulipristal acetate
7 Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy Unknown status NCT02288130 Phase 4 GnRHa;Ulipristal
8 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
9 The Effect of Ulipristal Acetate (UPA) on Women Ovarian Reserve Unknown status NCT02361892 Phase 4 ulipristal acetate
10 Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy Unknown status NCT01632202 Phase 4
11 Vaginal Misoprostol Versus Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy Unknown status NCT02643186 Phase 4 preoperative vaginal misoprostol
12 Fibroids in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
13 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
14 Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
15 A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
16 The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids. Completed NCT00995878 Phase 4
17 Efficacy Study of Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Large Fibroids Completed NCT00159328 Phase 4
18 A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy Recruiting NCT03210324 Phase 4 Mifepristone tablets
19 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
20 Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Recruiting NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
21 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
22 Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future Completed NCT00180739 Phase 4
23 Ulipristal Use in Chinese Population Active, not recruiting NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid
24 Misoprostol for Reduction of Blood Loss During Fibroid Surgery Recruiting NCT02209545 Phase 4 Misoprostol;Placebo
25 Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids Recruiting NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
26 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
27 Preemptive Analgesia Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
28 Combined Vaginal Misoprostol and Perivascular Vasopressin Recruiting NCT03815344 Phase 4 Standard;Standard-vaginal misoprostol
29 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
30 Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery Completed NCT01388907 Phase 4
31 Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial Completed NCT01393704 Phase 4 Vasopressin
32 Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx) Completed NCT02286063 Phase 4 Ambulatory Oxygen
33 Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
34 Comparing Two Types of Sedation to Gynaecological Patients Completed NCT01412632 Phase 4 Remifentanil, propofol and citanest
35 Peritoneal Cavity Conditioning Decreases Pain, Inflammation and Adhesions Terminated NCT01344486 Phase 4
36 Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy Completed NCT02154932 Phase 4 2 doses 400 microgram misoprostol;single dose misoprostol
37 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
38 Understanding Experimentally Induced Hot Flushes Completed NCT00455689 Phase 4 Leuprolide acetate
39 Impact of Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
40 Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery Enrolling by invitation NCT02812186 Phase 4 Rocuronium
41 Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids Unknown status NCT02189083 Phase 3 TSD
42 Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy Unknown status NCT01280045 Phase 3
43 Clinical Trial of Uterine Artery Embolization for Uterine Leiomyoma Unknown status NCT00821275 Phase 2, Phase 3
44 The Use of Doppler to Diagnose Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
45 Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy Unknown status NCT01483417 Phase 3
46 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
47 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
48 3D Sonohysterography vs Hysteroscopy: Study for the Evaluation of Intrauterine Abnormalities Unknown status NCT02682433 Phase 3
49 Intravenous Tranexamic Acid Versus Pericervical Tourniquet To Decrease Blood Loss In Trans-Abdominal Myomectomy Unknown status NCT02733952 Phase 3 Tranexamic Acid
50 Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound Withdrawn NCT02736435 Phase 3 leuprolide acetate for depot suspension

Search NIH Clinical Center for Leiomyoma, Uterine

Genetic Tests for Leiomyoma, Uterine

Genetic tests related to Leiomyoma, Uterine:

# Genetic test Affiliating Genes
1 Uterine Leiomyoma 29 HMGA2

Anatomical Context for Leiomyoma, Uterine

MalaCards organs/tissues related to Leiomyoma, Uterine:

41
Uterus, Smooth Muscle, Testes, Breast, Prostate, Bone, Liver

Publications for Leiomyoma, Uterine

Articles related to Leiomyoma, Uterine:

(show top 50) (show all 877)
# Title Authors Year
1
The effect of TGF-I^ signaling on regulating proliferation of uterine leiomyoma cell via ERI+ signaling activated by bisphenol A, octylphenol and nonylphenol <i>in vitro</i>. ( 29970676 )
2018
2
Placenta increta after high intensity-focused ultrasound for the treatment of a uterine leiomyoma. ( 29410151 )
2018
3
Deep sequencing reveals the molecular pathology characteristics between primary uterine leiomyoma and pulmonary benign metastasizing leiomyoma. ( 29484624 )
2018
4
The AKT/BCL-2 axis mediates survival of uterine leiomyoma in a novel 3D spheroid model. ( 29381777 )
2018
5
Clinical Predictors of Successful Vaginal Myomectomy for Prolapsed Pedunculated Uterine Leiomyoma. ( 29449196 )
2018
6
Establishment of a novel mouse xenograft model of human uterine leiomyoma. ( 29891843 )
2018
7
Association between fok1 polymorphism of vitamin D receptor gene with uterine leiomyoma in Turkish populations. ( 29391329 )
2018
8
Increased Risk of Venous Thromboembolism in Women with Uterine Leiomyoma: A Nationwide, Population-Based Case-Control Study. ( 29375226 )
2018
9
Spontaneous pregnancy during ulipristal acetate treatment of giant uterine leiomyoma. ( 28730656 )
2018
10
What MRI features suspect malignant pure mesenchymal uterine tumors rather than uterine leiomyoma with cystic degeneration? ( 29400019 )
2018
11
Peritoneal sarcomatosis 5 years after laparoscopic morcellation of uterine leiomyoma. ( 29338993 )
2018
12
Successful operative treatment of uterine leiomyoma with extensive intravenous extension to the IVC, right heart, and pulmonary arteries. ( 29338669 )
2018
13
Overexpression of the 14-3-3I^ protein in uterine leiomyoma cells results in growth retardation and increased apoptosis. ( 29382566 )
2018
14
Comment on: Delayed intestinal perforation and vertebral osteomyelitis after high-intensity focused ultrasound treatment for uterine leiomyoma. ( 29569640 )
2018
15
Malignant transformation of uterine leiomyoma to myxoid leiomyosarcoma after morcellation associated with <i>ALK</i> rearrangement and loss of 14q. ( 29963223 )
2018
16
Case of pulmonary benign metastasizing leiomyoma from synchronous uterine leiomyoma in a postmenopausal woman. ( 30225333 )
2018
17
Novel treatment avenues for uterine leiomyoma: a new implication for endothelin? ( 30301761 )
2018
18
Frequent milk and soybean consumption are high risks for uterine leiomyoma: A prospective cohort study. ( 30313022 )
2018
19
The current place of mini-invasive surgery in uterine leiomyoma management. ( 30316905 )
2018
20
Romina: A powerful strawberry with in vitro efficacy against uterine leiomyoma cells. ( 30317591 )
2018
21
MicroRNAs involved in the HMGA2 deregulation and its co-occurrence with MED12 mutation in uterine leiomyoma. ( 30376129 )
2018
22
Comparison of 30-day Complication Rates between Laparoscopic Myomectomy and Total Laparoscopic Hysterectomy for the Treatment of Uterine Leiomyoma in Women Older Than Age 40. ( 30385429 )
2018
23
Simvastatin, at clinically relevant concentrations, affects human uterine leiomyoma growth and extracellular matrix production. ( 30503138 )
2018
24
Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma. ( 30538295 )
2018
25
Patient-derived xenograft model for uterine leiomyoma by sub-renal capsule grafting. ( 30547045 )
2018
26
Successes and failures of uterine leiomyoma drug discovery. ( 29254389 )
2018
27
Size of uterine leiomyoma is a predictor for massive haemorrhage during caesarean delivery. ( 29494995 )
2018
28
A Statistical Approach to Detect Intrinsically Disordered Proteins Associated with Uterine Leiomyoma. ( 29577850 )
2018
29
Regulation of Cell Cycle Regulatory Proteins by MicroRNAs in Uterine Leiomyoma. ( 29642801 )
2018
30
Torsion of pedunculated subserous uterine leiomyoma: A rare complication of a common disease. ( 29673677 )
2018
31
Correction to: Jenabi and Fereidooni, The uterine leiomyoma and placenta previa: a meta-analysis. ( 29690803 )
2018
32
Cellular kinetics of MED12-mutant uterine leiomyoma growth and regression in vivo. ( 29700012 )
2018
33
Comparison of Nerve Fiber Density between Patients with Uterine Leiomyoma with and without Pain: a Prospective Clinical Study. ( 29720746 )
2018
34
Dysregulated chaperones associated with cell proliferation and negative apoptosis regulation in the uterine leiomyoma. ( 29731911 )
2018
35
RANKL/RANK Pathway and Its Inhibitor RANK-Fc in Uterine Leiomyoma Growth. ( 29741640 )
2018
36
Application of a 'Baseball' Suture Technique in Uterine Myomectomy Following Laparoscopic Enucleation of Uterine Leiomyoma (Fibroid). ( 29742071 )
2018
37
The Detection of Uterine Leiomyoma (Fibroid) Calcifications on 18F-NaF PET/CT. ( 29742599 )
2018
38
Association of BET1L and TNRC6B with uterine leiomyoma risk and its relevant clinical features in Han Chinese population. ( 29743541 )
2018
39
MicroRNA 21a-5p overexpression impacts mediators of extracellular matrix formation in uterine leiomyoma. ( 29747655 )
2018
40
Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study. ( 29765929 )
2018
41
Next-generation sequencing reveals differentially expressed small noncoding RNAs in uterine leiomyoma. ( 29778390 )
2018
42
Hypoxia Induces Hypoxia-Inducible Factor 1α and Potential HIF-Responsive Gene Expression in Uterine Leiomyoma. ( 29779471 )
2018
43
A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma. ( 29780819 )
2018
44
Analysis of the in vitro effects of di-(2-ethylhexyl) phthalate exposure on human uterine leiomyoma cells. ( 29805520 )
2018
45
Association of uterine leiomyoma and overactive bladder syndrome. ( 29862495 )
2018
46
Giant Uterine Leiomyoma in a Young Woman as an Incidental Finding After a Car Accident: a Case Report. ( 30012247 )
2018
47
LASH in Severely Enlarged Uterine Leiomyoma: Removal of a Uterus of 4065 g. ( 30046311 )
2018
48
Lung metastases from benign uterine leiomyoma: does 18-FDG-PET/CT have a role to play? ( 30074141 )
2018
49
Oxidative stress-induced miRNAs modulate AKT signaling and promote cellular senescence in uterine leiomyoma. ( 30097674 )
2018
50
XPG rs873601 G>A contributes to uterine leiomyoma susceptibility in a Southern Chinese population. ( 30139812 )
2018